Overview

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Status:
Not yet recruiting
Trial end date:
2023-10-09
Target enrollment:
Participant gender:
Summary
This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.